One notable finding was that only NSCLC patients with BRAF V600E mutations seem to benefit from BRAF-targeted therapies, while those with non-V600E BRAF mutations tend to respond less effectively to BRAF TKIs (18–20). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.